IN THE NEWS
DotLab, which developed a non-invasive diagnostic for endometriosis, announced a $10 million series A funding round. The women’s health company CooperSurgical led the round, marking a rare venture effort for the organization. While they are an active acquirer in the gynecology sector, they rarely invest in early-stage technologies, which emphasizes the strategic interest in this segment. They were joined by individual investors from Tiger Global Management and Luxor Capital Group, as well as Wilson Sonsini Goodrich & Rosati.
The company says they applied novel biomarkers combined with machine learning to develop their test, which improves upon the invasive, decades-old method of diagnosing endometriosis by laparoscopic surgery under general anesthesia. A non-invasive, widely-available diagnostic for endometriosis, which affects up to 10% of women worldwide and can contribute to infertility, could reduce costs and time to diagnosis for women with the painful condition.
According to co-founder and CEO Heather Bowerman, DotLab will use the funds from this round to “further clinical validation, expand market access, and continue to grow our team in the pursuit of our goals.” The company has already completed a clinical evaluation at Yale University to assess the performance of the test relative to laparoscopy in patients with and without endometriosis.
Posted: July 11, 2019
